Hepatitis C

Payer and Provider Workshops in HCV and HIV (Seattle, WA)

Nov. 14, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.

Payer and Provider Workshops in HCV and HIV (Indianapolis, IN)

Nov. 8, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.

Payer and Provider Workshops in HCV and HIV (Tampa, FL)

Oct. 24, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.

Payer and Provider Workshops in HCV and HIV (Atlanta, GA)

Oct. 12, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.

Payer and Provider Workshops in HCV and HIV (Salt Lake City, UT)

Oct. 11, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.

Payer and Provider Workshops in HCV and HIV (Portland, OR)

Oct. 10, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free dinner program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management. Identify approaches for better communication and efficient navigation of managed care requirements, and ways to leverage resources that can improve HCV and HIV care.

Recently Incarcerated Have High Rates of HCV and Little Help

Sept. 14, 2017

Integrated care in prison systems is key to reducing rates and transmission risk post-release.
Advertisement

Achalasia: It’s Not All About the Lower Esophageal Sphincter

Aug. 24, 2017

A 66-year-old man with cirrhosis secondary to hepatitis C and achalasia presented as a referral for evaluation and management.

Treating HCV in Incarcerated Populations Key to Disease Elimination

Aug. 17, 2017

Infection rates range from 9.6 percent to 41.1 percent. Read more in the AGA-MedPage Today Reading Room.

Risk Factors of Prednisolone May Outweigh Benefit in Treatment of Severe Alcoholic Hepatitis (SAH)

Aug. 17, 2017

Gastroenterology researchers discuss their findings in video abstract.

Previously Cured HCV Patients Can Be Reinfected

Aug. 3, 2017

Prevention will require attention to high-risk behaviors.

Make an Impact on World Hepatitis Day

July 27, 2017

World Hepatitis Day, July 28, is an opportunity to join in on the fight to end viral hepatitis.

Primary Care Providers Can Treat Hep C

July 24, 2017

Primary care physicians and nurse practitioners can achieve cure rates matching those of liver disease specialists.

Latest Issue of AGA Perspectives is Now Available

July 19, 2017

The new issue of AGA Perspectives examines the use of anti-TNF therapy, the promising outlook of stool DNA testing and revisits the gut microbiome of AGA members.

Looking at the Twin Epidemics of HCV

July 6, 2017

Younger cohorts at risk of HCV need more attention.

Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis

June 26, 2017

We performed an open-label, prospective, multicenter study of the effectiveness and tolerance of an all-oral, interferon- and ribavirin-free regimen of sofosbuvir plus daclatasvir in patients with HCV-associated CryoVas.

New WHO Report: More Work Needed to Diagnose, Treat Viral Hepatitis Worldwide

June 22, 2017

Just 20 percent of people with hepatitis C have been diagnosed, and only 7 percent have been treated.

Member Benefit Spotlight: GastroSlides

June 15, 2017

Free access to AGA's GastroSlides is now a member benefit.

Course for NPs and PAs Benefits All Experience Levels

June 14, 2017

Find out how AGA's popular course, Principles of GI for the NP and PA, benefits all those who attend, regardless of experience level or practice setting.

Canadian HCV Screening Guidelines Do Not Include Baby Boomers

June 8, 2017

Controversial guidelines spark debate.

AGA Releases New HCV Care Pathway

June 6, 2017

The AGA Hepatitis C Virus (HCV) Infection Care Pathway provides guidance regarding the best practices for managing U.S.-based patients with HCV.

Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus–Induced Cryoglobulinemia Vasculitis

June 1, 2017

We analyzed blood samples from patients with HCV-CV before and after DAA therapy to determine mechanisms of these drugs and their effects on cellular immunity.

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving

June 1, 2017

We found treatment of HCV genotype 1 infection with second-generation DAAs to be cost-effective when they cost less than and $227,200.

New Hepatitis C Treatment Not Linked to Liver Cancer

May 25, 2017

Contrary to some earlier research, most recent studies see no association between response to DAAs and HCC.